The present invention provides therapies for allergies. Specifically, the compositions of the present invention comprise engineered T cells comprising a chimeric antigen receptor that binds an IgE-BCR presented on B cells but not a secreted IgE. Therefore, the T cells eliminate IgE-producing B cells, prevent secretion of IgE and subsequently the symptoms of allergy.

New synthetic expression cassettes comprising a minimal promoter and a cell-specific enhancer for expression of a nucleic acid of interest in one or more specific cell subtypes are disclosed. Vectors and host cells comprising such synthetic expression cassettes are also disclosed. The application also discloses methods for expressing a nucleic acid of interest, such as a nucleic acid encoding a chimeric antigen receptor (CAR), in a cell and for treating diseases or conditions such as cancers and genetic diseases using the synthetic expression cassettes, vectors and cells.

The present application describes T cell receptors specifically binding tumor antigen derived peptides, especially derived from Mitogen-Activated Protein Kinase 8 Interacting Protein 2 (MAPK8IP2), Epstein-Barr Virus (EBV) proteins or Human Endogenous Retrovirus (HERV), as well as engineered T cells expressing these receptors, nucleic acids encoding these T cell receptors and methods of using T cells expressing these engineered T cells in adoptive cell transfer to treat diseases in a subject.

The present invention features fratricide resistant modified immune cells (e.g., T- or NK-cells) having enhanced anti-neoplasia activity and methods for producing and using the same. Methods of treating neoplasia (e.g., T- or NK-cell malignancies) using fratricide resistant modified immune cells are also provided.

A method of transducing a T cell with a viral vector includes contacting the T cell with the viral vector and an agent capable of inhibiting the innate anti-virus activity of the T cell. A method of preparing CAR- T cells includes providing cells and transducing the T cells with a viral vector including a nucleotide sequence encoding a chimeric antigen receptor in the presence of an agent capable of inhibiting the innate anti-virus activity of the T cells. The methods of transducing T cells can increase transduction rate and/or prevent the decrease of transduction rate during subsequent cell expansion process.

The invention provides Natural Killer (NK) cells that have a reduced or ablated Signal Regulatory Protein Alpha (SIRP) function when compared to a NK cell having an unmodified SIRP function that effectively kills a population of cancer cells that express CD47.

The present invention relates generally to a fusion protein that when displayed on a cell can convert a negative signal into a positive signal in the cell. The fusion protein is a chimeric protein in that the protein comprises at least two domains, wherein the first domain is a polypeptide that is associated with a negative signal and the second domain is a polypeptide that is associated with a positive signal. Thus, the invention encompasses switch receptors that are able to switch negative signals to positive signals for enhancement of an immune response.

The present invention relates to the field of biomedicine, and in particular, the present invention relates to an antibody or antigen-binding fragment thereof which specifically binds to MSLN, and a chimeric antigen receptor (CAR) comprising said antibody or antigen-binding fragment thereof. The present invention also relates to modified immune cells expressing said CAR, or co-expressing said CAR and additional bioactive molecules (e.g. PD-1 antibody and/or mIL-15), and a method for preparing said modified immune cells. The present invention also relates to the use of such antibodies, CARs, and immune cells for the prevention and/or treatment of diseases associated with the expression of mesothelin, such as malignant pleural mesothelioma, pancreatic cancer, lung cancer, breast cancer, and ovarian cancer, and a method for the prevention and/or treatment of diseases associated with the expression of mesothelin, such as malignant pleural mesothelioma, pancreatic cancer, lung cancer, breast cancer, ovarian cancer, and other MSLN-positive tumors.

The present invention relates to a programmed cell death protein 1 (anti-PD-1) antibody or an antigen-binding fragment thereof; a nucleic acid encoding same; a recombinant expression vector containing the nucleic acid; host cells transfected with the recombinant expression vector; a method for preparing the antibody or the antigen-binding fragment thereof; a bispecific or multispecific antibody comprising the antibody or the antigen-binding fragment thereof; an immune cell engaging bispecific or multispecific antibody comprising at least one scFv of the antibody and at least one scFv of an antibody binding to an immune cell activating antigen; an antibody-drug conjugate (ADC) in which the antibody or the antigen-binding fragment thereof is bound to a drug; a chimeric antigen receptor (CAR) comprising the scFv of the anti-PD-1 antibody as an antigen-binding site of an extracellular domain; immune cells into which the chimeric antigen receptor is introduced; a composition for combination therapy comprising the immune cells; a composition for combination therapy comprising the antibody or the antigen-binding fragment thereof; a composition for the treatment of cancer; and a method for treating cancer.

The present disclosure relates to low affinity chimeric antigen receptors (CARs) and CAR-T cells, which provide cytotoxicity against tumors overexpressing the proto-oncogene c-MET and alleviate on-target, off-tumor toxicities. The CAR-T cells of the present disclosure comprise low affinity anti-c-MET scFvs, which facilitate enhanced anti-tumor activity and a reduced rate of tumor relapse.